INTRODUCTION
The diazepam binding inhibitor (DBI) is a 10 kDa highly conserved protein that is widely distributed throughout phylogenesis from yeast to mammals [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and that has been proposed to have multiple biological functions.
Originally, DBI was purified from rat brain on the basis of its ability to displace diazepam from type A y-aminobutyrate receptor (GABAA) [12] . Pharmacological and electrophysiological studies, together with intracerebroventricular injection experiments in rats and increased DBI concentrations in cerebrospinal fluid in several mental disorders involving changes in GABAergic transmission, have suggested that DBI might be involved in the endogenous modulation of the GABAA-benzodiazepine receptor complex (see [13] for a review, [14] ).
Furthermore, a 10 kDa protein purified from bovine liver and capable of binding and inducing synthesis of acyl-CoA, turned out to be identical with DBI and was named acyl-CoA-binding protein [15] . Structural studies as well as extensive functional studies in vitro and in vivo have provided strong evidence that DBI acts as a pool former and/or a transporter of acyl-CoA (see [16] for a review). The involvement of DBI in acyl-CoA metabolism has received further support from the observation that in Drosophila melanogaster, DBI is only expressed in tissues with a high level of energy consumption, utilizing fatty acids as its primary energy source [10] .
DBI has also been purified from bovine adrenal gland on the basis of its stimulatory effect on mitochondrial steroidogenesis [17, 18] . The steroidogenic effect of DBI has been demonstrated in vitro with mitochondrial preparations from several tissue culture cell lines [19, 20] and such effect was proposed to be caused by stimulation of cholesterol delivery to the inner mitochondrial membrane [17] . Also, antisense oligonucleotides to DBI have been shown to inhibit hormone-stimulated steroid production in Leydig cells [21] .
DBI purified from porcine intestine has been shown to decrease glucose-stimulated insulin release [4, 22, 23] . One of the DBI processing products (DB132 86) has been shown to have antibacterial properties [24] .
In humans and other mammals the DBI protein consists of 86 amino acids [2, 3, 4, 5, 15, 25, 26] . In addition to the cDNA encoding encoding polypeptides of 86 and 104 amino acids were detected in all the human tissues and cell lines studied. The transcript coding for the 86 amino acid DBI polypeptide was found to represent the majority of the total DBI transcript pool.
for DBI of 86 amino acids [25] , a human DBI cDNA capable of encoding the protein with 104 amino acids has also been cloned [1] . These different cDNA clones will here be referred to as hDBI-1 [25] and hDBI-2 [1] , respectively. So far there is no conclusive evidence of the existence of the hDBI-2 polypeptide or of the expression of the corresponding transcript in human tissues. Nothing is known either about the possible biological function(s) of this putative 104 amino acid DBI polypeptide.
This paper describes the expression of two different DBI transcripts in human tissues and tissue culture cell lines using reverse-transcriptase assisted PCR (RT/PCR) and RNase protection assay.
EXPERIMENTAL

RNA preparations and cell lines
The preparation of RNAs from adrenal gland, pancreas, lymphocytes, jejunum, duodenum, heart, kidney and tissue culture cell lines IMR-32 and HS 67 has been described previously [27] . All other RNAs were prepared as described [28] . The following human cell lines were used: Chang (non-malignant liver), IMR-32 (neuroblastoma), Hs 67 (normal thymus), MG-63 (osteosarcoma) and Jurkat (acute T-cell leukaemia).
cDNA cloning and PCR cDNA first strand was synthesized in a total volume of 20 ,ul, by oligo-dT priming, with M-MuLV reverse transcriptase (Promega), using 2,ug of the total RNA as a template. Negative controls were carried out with each RNA preparation by omitting reverse transcriptase from the first strand synthesis reaction.
PCR was carried out in a volume of 50 ,ul, using 2 ,tl of the cDNA first strand synthesis reaction mixture as a template. The reaction mixture was denatured at 96°C for 4 min and amplified for 30 cycles: 94°C for 1 min, 58°C for 1 min and 72°C for 1 min. The last polymerization step was extended to 11 min.
The primers used for PCR were as follows: the 5' primer for hDBI-1 was GACCTCGAGGTCGGCCAGGATGTCTCAGG Abbreviations used: DBI, diazepam binding inhibitor; RT/PCR, reverse-transcriptase assisted PCR; GABAA, type A y-aminobutyrate receptor.
* To whom correspondence should be addressed. [25] ; the 5' primer for hDBI-2 was GACCTCGAGACCGAG-CTATGTGGGGCGAC [1] ; and the 3' primer used for both transcripts was GTCGAATTCGGCATCTTCCTTGGAAGT-CC [1, 25] . The primers included XhoI and EcoRI restriction sites (5' primers and 3' primer, respectively).
For cDNA cloning the 5' primers were the same as described above but the 3' primer was TTCCCGAATTCCCACCATCC [1] . Amplified DNA fragments were digested with XhoI/EcoRI (the XhoI site is in the 5' primers and EcoRI site is located in the 3' untranslated region of the DBI transcript) and cloned into pBluescript II KS-vector (Stratagene). Cloned cDNA sequences were verified by DNA sequencing using the chain-termination method [29] and analysed with an ALF automated DNA sequencer (Pharmacia). The DNA sequence data were analysed by GCG software [30] .
RNase protection analysis 
RESULTS AND DISCUSSION
To study the expression of DBI transcripts by RT/PCR, two different primers were designed to cover the 5' ends of the previously published different human DBI cDNAs [1, 25] . One common oligonucleotide was used as the 3' primer (see the Experimental section). Analysis of the total RNA from different tissues revealed the presence of two different amplification products of the expected sizes (237 bp for hDBI-1 and 287 bp for hDBI-2) in all the tissues studied: brain, liver, adrenal gland, pancreas, lymphocytes, jejunum, duodenum, heart and kidney ( Figure 1 The cRNA probes used in the RNase protection assay share 127 nucleotide identity and 17 and 69 nucleotide difference at their 5' ends respectively (see the Experimental section). If both RNA transcripts are expressed, then both of the probes should yield two protected fragments. A protected fragment of 127 nucleotides, corresponding to identical regions in P1 and P2, should appear with both probes. In addition, P1 should yield a fragment of 144 nucleotides (corresponding to hDBI-1), and P2 should yield a fragment of 196 nucleotides (corresponding to hDBI-2, see also Figure 2 ). Protected fragments corresponding to the hDBI-1 transcript (144 and 127 nucleotides for P1 and P2 respectively) were detected in all the tissues and cell lines studied (Figure 3) . The signal from the protected fragment corresponding to the hDBI-2 transcript (127 for P1 and 196 for P2) is markedly weaker than that of hDBI-l (Figure 3a, b) , indicating that the hDBI-2 represents only a minor fraction of a total pool of the human DBI transcripts.
Our results showing the expression of DBI transcripts in all the human tissues studied are consistent with the findings of an earlier study which revealed expression of DBI-like immuno- reactivity in human brain and several peripheral tissues [33] . DBI is also expressed in almost all rat tissues studied so far [34, 35] . In previous studies the expression of human DBI transcripts has been investigated by Northern blot hybridization. Size heterogeneity in 5' and 3' untranslated regions of transcripts (variable length of the poly-A tail and most probably multiple transcriptional starting-points as has been reported for rat DBI [31, 32] Filled boxes represent coding exons 1 and 2 in the rat DBI gene. The striped box indicates the location of a highly homologous nucleotide sequence in the first intron of the rat DBI gene as compared with the cDNA sequence encoding the hDBI-2 N-terminus. The computer translated amino acid sequence of the respective region is designated as Rl and was translated from a nucleotide sequence with accession number Z21846. Deletion of a T nucleotide at position 1585 was introduced into the first intron of the rat DBI gene prior to translation to obtain optimal protein sequence alignment. hDBI-1 and hDBI-2 represent a protein sequence translated from [25] and [1 ] respectively. Identical amino acids are indicated by dots. The numbers correspond to the numbering of the nucleotide sequence with the accession number Z21846. The numbers indicate the size of the molecular mass markers in kDa.
and cause DBI messages to be detected as a single broad band of 0.6-0.8 kb on Northern blots [1, 25] . We have shown here that a DBI transcript capable of encoding a protein of 104 amino acids (corresponding to hDBI-2 cDNA) is expressed in all the human tissues and cell lines studied.
Several studies suggest that these two different DBI transcripts are most likely transcribed from one single gene. First, chromosomal localization experiments of the DBI gene have shown that there is a single functional gene and several pseudogenes in the human genome [36] . Secondly, an extensive nucleotide sequence identity extends throughout most of the coding region and the 3' untranslated region of DBI transcripts. Thirdly, a highly homologous region exists in the first intron of the rat DBI gene compared with the sequence encoding the N-terminal part of the hDBI-2 cDNA [31; M. Kolmer and H. Alho, unpublished work]. However it has been shown by RNase protection assay that in rat a sequence homologous to the first coding exon of the hDBI-2 is excluded from mature DBI mRNA [31] . Partial protein sequences translated from two different DBI cDNA clones and homologous regions of rat DBI gene are presented in Figure 4 .
Different DBI transcripts arise due to alternative usage of the first coding exon. Our data clearly show that the hDBI-I transcript represents the majority of DBI transcripts. As the human DBI gene remains to be cloned and its promoter(s) to be characterized one can only hypothesize what the mechanisms are that cause such a dramatic difference between two transcript species. One possible explanation is that there are two promoters with different strengths. The other possibility is that the 5' splice following the alternatively spliced first coding exon of hDBI-I is favoured over the corresponding hDBI-2 site.
We also studied the translatability of the DBI transcripts in vitro. As was revealed by transcription-coupled translation experiments, both DBI transcripts were translated into fulllength proteins of the expected sizes and no differences were detected in translation efficiencies from different cDNA clones ( Figure 5 ). However, possible differences in translational efficiencies in vivo, due to different 5' untranslated sequences, could not be excluded.
In conclusion, we have shown that in the human, DBI transcripts are expressed in all the tissues and cell lines studied. We have also established here for the first time the presence of another DBI 
